DISAPPOINTING DATA: In the latest setback in Alzheimer’s research, an experimental drug failed the first of four late-stage studies. The treatment didn’t slow mental or functional decline in patients with mild or moderate Alzheimer’s who carry a gene that increases the risk of the disease.
WHAT’S NEXT: Development partners Pfizer Inc. and Johnson & Johnson will continue three other late-stage tests of bapineuzumab. Two studies are in patients who don’t have the ApoE4 gene.
WHAT’S AT STAKE: There’s no treatment that does more than temporarily ease Alzheimer’s symptoms, which afflict about 5 million Americans.